NKARTA INC (NKTX) Stock Price & Overview
NASDAQ:NKTX • US65487U1088
Current stock price
The current stock price of NKTX is 2.36 USD. Today NKTX is up by 1.72%. In the past month the price decreased by -5.6%. In the past year, price increased by 49.84%.
NKTX Key Statistics
- Market Cap
- 167.631M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.40
- Dividend Yield
- N/A
NKTX Stock Performance
NKTX Stock Chart
NKTX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to NKTX. When comparing the yearly performance of all stocks, NKTX is one of the better performing stocks in the market, outperforming 84.75% of all stocks.
NKTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NKTX. No worries on liquidiy or solvency for NKTX as it has an excellent financial health rating, but there are worries on the profitability.
NKTX Earnings
NKTX Forecast & Estimates
12 analysts have analysed NKTX and the average price target is 12.04 USD. This implies a price increase of 410% is expected in the next year compared to the current price of 2.36.
NKTX Groups
Sector & Classification
NKTX Financial Highlights
Over the last trailing twelve months NKTX reported a non-GAAP Earnings per Share(EPS) of -1.4. The EPS increased by 15.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.75% | ||
| ROE | -33.33% | ||
| Debt/Equity | 0 |
NKTX Ownership
NKTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.93 | 365.463B | ||
| AMGN | AMGEN INC | 15.01 | 184.669B | ||
| GILD | GILEAD SCIENCES INC | 15.85 | 173.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.325B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.32 | 80.669B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.27 | 43.81B | ||
| INSM | INSMED INC | N/A | 35.309B | ||
| NTRA | NATERA INC | N/A | 29.036B | ||
| BIIB | BIOGEN INC | 10.72 | 25.293B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.74 | 24.53B | ||
| MRNA | MODERNA INC | N/A | 19.261B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.898B | ||
| INCY | INCYTE CORP | 12.39 | 18.878B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NKTX
Company Profile
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 105 full-time employees. The company went IPO on 2020-07-10. The firm is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
Company Info
IPO: 2020-07-10
NKARTA INC
1150 Veterans Boulevard
South San Francisco CALIFORNIA 94080 US
CEO: Paul J. Hastings
Employees: 105
Phone: 19254071049
NKARTA INC / NKTX FAQ
What does NKARTA INC do?
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 105 full-time employees. The company went IPO on 2020-07-10. The firm is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
What is the stock price of NKARTA INC today?
The current stock price of NKTX is 2.36 USD. The price increased by 1.72% in the last trading session.
What is the dividend status of NKARTA INC?
NKTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of NKTX stock?
NKTX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for NKTX stock?
NKARTA INC (NKTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.4).
Can you provide the market cap for NKARTA INC?
NKARTA INC (NKTX) has a market capitalization of 167.63M USD. This makes NKTX a Micro Cap stock.
When does NKARTA INC (NKTX) report earnings?
NKARTA INC (NKTX) will report earnings on 2026-05-12.